title: Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.
abstract: OBJECTIVE
  To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity.
  
  
  METHODS
  Randomized, double-blind, multicenter, placebo-controlled study.
  
  
  METHODS
  Eight centers across Belgium, France, and Switzerland.
  
  
  METHODS
  Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled.
  
  
  METHODS
  Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo.
  
  
  METHODS
  I-QOL questionnaire completed at screening and over a 24-week post-treatment period.
  
  
  RESULTS
  The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points.
  
  
  CONCLUSIONS
  Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
authors.affiliation: Spinal Cord Injury Center, University Hospital Balgrist, Zurich, Switzerland. bschurch@paralab.balgrist.ch
authors.forename: Brigitte
authors.initials: B
authors.lastname: Schurch
authors.forename: Pierre
authors.initials: P
authors.lastname: Denys
authors.forename: Chris M
authors.initials: CM
authors.lastname: Kozma
authors.forename: Pat Ray
authors.initials: PR
authors.lastname: Reese
authors.forename: Terra
authors.initials: T
authors.lastname: Slaton
authors.forename: Rich
authors.initials: R
authors.lastname: Barron
mesh_terms: D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D011594:Psychometrics / Q000379:methods; D011788:Quality of Life; D015203:Reproducibility of Results; D013119:Spinal Cord Injuries / Q000150:complications; D011795:Surveys and Questionnaires; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy / Q000209:etiology / Q000523:psychology*
chemical_list: D019274:Botulinum Toxins, Type A